Gsk Plc ADR (GSK)

$54.44 -1.19 (-2.14%)
Market Cap 112.88B
Revenue (ttm) 43.08B
Net Income (ttm) 7.54B
EPS (ttm) N/A
PE Ratio 12.32
Forward PE 11.59
Profit Margin 17.50%
Debt to Equity Ratio 1.11
Volume 5,048,800
Avg Vol 4,685,756
Day's Range N/A - N/A
Shares Out 2.03B
Stochastic %K 5%
Beta 0.46
Analysts Sell
Price Target $56.45

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 8047 5000
Website: www.gsk.com
Address:
79 New Oxford Street, London, United Kingdom
FutureOutlook1
FutureOutlook1 Apr. 25 at 4:09 PM
$GSK pharmaceutical leader with diversified healthcare revenue and defensive characteristics
0 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 10:19 PM
$SPRO Merger Monday incoming? In addition to anecdote below, Spero still hasn't filed their definitive proxy (usually 10-11 days after the preliminary). I could see $10-$12/share. I've seen 300-350% premiums in microcap biotech before but have hard time imagining a bigger premium than that. The math should be pretty easy, avoid 325 million milestones and maybe 175 million/ + royalties on peak annual tebi sales to 2041. (estimated by $GSK ) So pay 800 million to avoid 2.5 billion + future royalties/milestones? Let's go.
0 · Reply
Buy_SoFi
Buy_SoFi Apr. 24 at 7:52 PM
$1.00+ by EoY Ferring already partnered with $TLTFF and I can only assume the new cohort of test patients are in the process of being treated for NMIBC. More partners will probably knock on the door; MIBC, GBM/Brain, Lung, pancreatic and HSV topical treatment. This has a multi-dollar buyout written all over... $IBRX $GSK $CGON $JNJ
0 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 5:42 PM
$SPRO totally anecdotal and likely confirmation bias -- but did quick search on LinkedIn "reactions" on Spero posts. Historically 3-5 Board members react, and Esther. For the March post, only the COB reacted. Looked at various board member profiles and it is not like they aren't active on LinkedIn -- they've all been reacting to stuff as recently as this week including Esther. Wonder if they are purposefully avoiding SPRO social media posts. Just a random observation. cc $GSK
0 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 3:59 PM
Crazy how correlated / linked $GSK $SPRO are but it does makes sense. GSK might have started its reversal into its earnings report next week. SPRO saw little buying pressure at same time
1 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 1:51 PM
$CGEN wins the first lap to 3 $SPRO weak along with $GSK
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 23 at 11:26 PM
REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge $REGN $LLY $GSK $ABBV $AMGN https://stocktwits.com/news/equity/markets/regn-becomes-final-major-drugmaker-to-sign-trump-s-drug-pricing-pledge/cZBQQQSReT5
0 · Reply
zerodayrounder
zerodayrounder Apr. 23 at 10:42 PM
$SPRO still riding the moving averages higher (9ema, 20/50/200sma), 4 green weekly bars. Pullbacks on light volume vs hard rejection. These guys really should sell ahead of PDUFA -- I'm sure they are good this time with $GSK leading the process -- but don't need another SPRO 2022 or GRCE from today. Makes no sense to give a caretaker CEO the keys to huge amount of capital to fund risky new ventures when all the scientists were let go. Could she really articulate on Q1 earnings call the strategy moving forward and why investors should vote yes on Proposal 4? She's got huge options/RSUs to go riding off to Cape Cod or the Hamptons this summer. and the CEO/corporate counsel apparently weren't participating in woke corporate social responsibility on the Charles River Esplanade yesterday.
0 · Reply
SnapCrackleStop
SnapCrackleStop Apr. 23 at 10:25 PM
$SCYX I am cautiously optimistic. The attack was feeble and we rose in the worst of market days. Some encouraging signs. We will see revenue from $GSK this year. I don’t see the stock declining below $1 significantly if at all. The shares are up from .69 and chart is telling us that more gains lie ahead. I think the reverse split will not be imposed or needed. The share count has no real affect on business performance. Trials continue pre funded through 2027 or longer. I think the stock is under accumulation by some big boys. The private placement/ warrant deal is going to benefit longstanding holders not shorts as warrant deals sometimes do. These institutional players are in for a multi bagger. Not just a double your money. No, this is something much greater. As mentioned….I am optimistic to say the least. $$$
1 · Reply
Buy_SoFi
Buy_SoFi Apr. 23 at 6:01 PM
$TLTFF <---- Multi-multi bagger in the making. Mark this post. $CGON $MRK $IBRX $GSK
0 · Reply
Latest News on GSK
GSK Faces Legal Setback as AnaptysBio Wins Court Ruling

2026-04-24T21:27:17.000Z - 23 hours ago

GSK Faces Legal Setback as AnaptysBio Wins Court Ruling

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

2026-04-24T19:40:00.000Z - 1 day ago

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest

Fri, 24 Apr 2026 03:28:20 -0400 - 1 day ago

Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest

Mandelson’s lobbying firm Global Counsel went bust owing £4.6m, report says

2026-04-23T16:26:47.000Z - 2 days ago

Mandelson’s lobbying firm Global Counsel went bust owing £4.6m, report says

FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings

Thu, 23 Apr 2026 05:50:35 -0400 - 2 days ago

FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings

GSK Secures Approval for Blenrep in China for Multiple Myeloma Treatment

2026-04-20T12:32:43.000Z - 5 days ago

GSK Secures Approval for Blenrep in China for Multiple Myeloma Treatment

GSK Reports Promising Phase I Results for Novel Cancer Treatment

2026-04-13T12:31:36.000Z - 12 days ago

GSK Reports Promising Phase I Results for Novel Cancer Treatment

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

2026-04-13T11:00:00.000Z - 12 days ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50%

2026-04-13T10:36:06.000Z - 12 days ago

GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50%

GSK Reports Promising Early Data For Experimental Cancer Drug

2026-04-13T09:50:15.000Z - 12 days ago

GSK Reports Promising Early Data For Experimental Cancer Drug

GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer

2026-04-13T01:46:18.000Z - 12 days ago

GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer

GSK Shifts Strategy with Five Late-Stage Trials for Promising Cancer Drug

2026-04-12T21:57:31.000Z - 12 days ago

GSK Shifts Strategy with Five Late-Stage Trials for Promising Cancer Drug

GSK reports promising early results in ovarian and womb cancer drug trial

2026-04-12T15:02:28.000Z - 13 days ago

GSK reports promising early results in ovarian and womb cancer drug trial

GSK sees blockbuster potential in targeted cancer therapy after promising early data

Sun, 12 Apr 2026 10:12:03 -0400 - 13 days ago

GSK sees blockbuster potential in targeted cancer therapy after promising early data

GSK Withdraws Approval for Wellcovorin Drug Amid Market Changes

2026-04-10T07:58:45.000Z - 15 days ago

GSK Withdraws Approval for Wellcovorin Drug Amid Market Changes

GSK (GSK) Withdraws Leucovorin Calcium Application from FDA

2026-04-09T20:50:41.000Z - 15 days ago

GSK (GSK) Withdraws Leucovorin Calcium Application from FDA

GSK withdrew an application of a drug touted by Trump and RFK Jr. as a potential treatment for autism. The drug's label last month was updated so that generic versions of it can be marketed for a rare genetic, neurological condition, but not autism.

Apr 9, 2026, 3:07 PM EDT - 16 days ago

GSK withdrew an application of a drug touted by Trump and RFK Jr. as a potential treatment for autism. The drug's label last month was updated so that generic versions of it can be marketed for a rare genetic, neurological condition, but not autism.

GSK

GSK (GSK) Gains Approval for Exdensur in China, Stock Rises

2026-04-08T22:03:50.000Z - 16 days ago

GSK (GSK) Gains Approval for Exdensur in China, Stock Rises

GSK Secures Chinese Approval for Exdensur in CRSwNP Treatment

2026-04-08T11:50:53.000Z - 17 days ago

GSK Secures Chinese Approval for Exdensur in CRSwNP Treatment

GSK Announces Completion Of Pfizer's Exit Of Its Investment In ViiV Healthcare

2026-04-01T06:35:40.000Z - 24 days ago

GSK Announces Completion Of Pfizer's Exit Of Its Investment In ViiV Healthcare

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

Mar 31, 2026, 10:00 AM EDT - 25 days ago

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

GSK

GSK Achieves Approval in China for Asthma Treatment Exdensur

2026-03-30T22:08:16.000Z - 25 days ago

GSK Achieves Approval in China for Asthma Treatment Exdensur

GSK (GSK) Seeks Chinese Approval for New Hepatitis B Treatment

2026-03-30T22:08:00.000Z - 25 days ago

GSK (GSK) Seeks Chinese Approval for New Hepatitis B Treatment

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 26 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PFE PPH

GSK Announces Approval For Exdensur In China

2026-03-30T06:13:09.000Z - 26 days ago

GSK Announces Approval For Exdensur In China

GSK: European Medicines Agency To Review MAA For Bepirovirsen

2026-03-27T07:56:31.000Z - 4 weeks ago

GSK: European Medicines Agency To Review MAA For Bepirovirsen

GSK PLC (GSK) Stock Price Up 3.7% on Mar 25

2026-03-25T18:00:08.000Z - 4 weeks ago

GSK PLC (GSK) Stock Price Up 3.7% on Mar 25

Clover Biopharmaceuticals Reports Positive U.S. Phase I Data On RSV Re-Vaccination In Older Adults

2026-03-25T01:14:37.000Z - 4 weeks ago

Clover Biopharmaceuticals Reports Positive U.S. Phase I Data On RSV Re-Vaccination In Older Adults

GSK (GSK) Antibody-Drug Conjugate Gains Orphan Drug Status in Japan

2026-03-23T11:51:36.000Z - 4 weeks ago

GSK (GSK) Antibody-Drug Conjugate Gains Orphan Drug Status in Japan

Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal

2026-03-20T14:13:56.000Z - 5 weeks ago

Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal

GSK Secures FDA Approval for Lynavoy in Treating PBC-Related Itch

2026-03-19T13:38:49.000Z - 5 weeks ago

GSK Secures FDA Approval for Lynavoy in Treating PBC-Related Itch

US FDA approves GSK's drug for liver disease related itching

Mar 19, 2026, 8:08 AM EDT - 5 weeks ago

US FDA approves GSK's drug for liver disease related itching

GSK

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 5 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Myriad Genetics Gains FDA Nod For Ovarian Cancer Test

2026-03-18T01:07:20.000Z - 5 weeks ago

Myriad Genetics Gains FDA Nod For Ovarian Cancer Test

Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report

2026-03-16T11:19:54.000Z - 5 weeks ago

Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report

GSK and Amgen to add medicines to TrumpRx, Fox Business reports

Mar 13, 2026, 8:27 PM EDT - 6 weeks ago

GSK and Amgen to add medicines to TrumpRx, Fox Business reports

AMGN GSK

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

Mar 13, 2026, 11:44 AM EDT - 6 weeks ago

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

GSK

GSK gets US FDA approval for expanded use of RSV vaccine

Mar 13, 2026, 7:03 AM EDT - 6 weeks ago

GSK gets US FDA approval for expanded use of RSV vaccine

GSK

FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder

Mar 10, 2026, 11:16 AM EDT - 6 weeks ago

FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder

GSK

FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year

Mar 10, 2026, 11:05 AM EDT - 6 weeks ago

FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year

GSK

US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptoms

Mar 10, 2026, 9:04 AM EDT - 6 weeks ago

US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptoms

GSK

FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment

Mar 10, 2026, 9:00 AM EDT - 6 weeks ago

FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment

GSK

GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million

Mar 9, 2026, 3:39 AM EDT - 6 weeks ago

GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million

GSK

GSK licenses liver disease drug to Italy's Alfasigma

Mar 9, 2026, 3:16 AM EDT - 6 weeks ago

GSK licenses liver disease drug to Italy's Alfasigma

GSK

GSK to Buy 35Pharma for $950 Million

Feb 25, 2026, 5:05 AM EST - 2 months ago

GSK to Buy 35Pharma for $950 Million

GSK

GSK to buy 35Pharma for $950 million

Feb 25, 2026, 2:18 AM EST - 2 months ago

GSK to buy 35Pharma for $950 million

GSK

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

Feb 25, 2026, 2:00 AM EST - 2 months ago

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

GSK

Frontier Biotechnologies strikes up to $1 billion deal with GSK

Feb 24, 2026, 6:21 AM EST - 2 months ago

Frontier Biotechnologies strikes up to $1 billion deal with GSK

GSK

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Feb 23, 2026, 1:13 PM EST - 2 months ago

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

GSK

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Feb 18, 2026, 8:00 AM EST - 2 months ago

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

GSK

3 International Stocks to Buy for 2026

Feb 5, 2026, 9:00 AM EST - 2 months ago

3 International Stocks to Buy for 2026

DEO SAP

GSK's Specialty Medicines Drive Solid Results

Feb 4, 2026, 2:45 AM EST - 2 months ago

GSK's Specialty Medicines Drive Solid Results

GSK forecasts slower sales growth in 2026

Feb 4, 2026, 2:03 AM EST - 2 months ago

GSK forecasts slower sales growth in 2026

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

Feb 2, 2026, 2:16 PM EST - 2 months ago

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

WVE

Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK

Jan 30, 2026, 3:00 AM EST - 3 months ago

Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK

SHEL VOD

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Jan 21, 2026, 10:00 AM EST - 3 months ago

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

Jan 20, 2026, 2:13 PM EST - 3 months ago

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

RAPT

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Jan 20, 2026, 9:00 AM EST - 3 months ago

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

GSK to buy food allergy drug maker RAPT in $2.2bn deal

Jan 20, 2026, 7:20 AM EST - 3 months ago

GSK to buy food allergy drug maker RAPT in $2.2bn deal

RAPT

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

Jan 20, 2026, 5:07 AM EST - 3 months ago

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

Jan 20, 2026, 2:55 AM EST - 3 months ago

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

Jan 20, 2026, 2:48 AM EST - 3 months ago

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

GSK to buy RAPT Therapeutics for $2.2 billion

Jan 20, 2026, 2:11 AM EST - 3 months ago

GSK to buy RAPT Therapeutics for $2.2 billion

RAPT

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 3 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

SMMT

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Jan 8, 2026, 7:09 PM EST - 3 months ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

ANAB

GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development

Jan 8, 2026, 9:00 AM EST - 3 months ago

GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

Jan 7, 2026, 11:48 AM EST - 3 months ago

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

IONS

GSK's chronic hepatitis B treatment meets main goal in key studies

Jan 7, 2026, 2:09 AM EST - 3 months ago

GSK's chronic hepatitis B treatment meets main goal in key studies

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 4 months ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

LLY NVS PFE SNY

Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln

Dec 21, 2025, 5:56 PM EST - 4 months ago

Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Dec 21, 2025, 5:43 PM EST - 4 months ago

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 4 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY MRK AMGN GILD NVS SNY

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 4 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD MRK NVS SNY

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 4 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD MRK NVS SNY

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Dec 16, 2025, 9:55 PM EST - 4 months ago

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

US FDA approves GSK's twice-yearly asthma drug

Dec 16, 2025, 6:10 PM EST - 4 months ago

US FDA approves GSK's twice-yearly asthma drug

FutureOutlook1
FutureOutlook1 Apr. 25 at 4:09 PM
$GSK pharmaceutical leader with diversified healthcare revenue and defensive characteristics
0 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 10:19 PM
$SPRO Merger Monday incoming? In addition to anecdote below, Spero still hasn't filed their definitive proxy (usually 10-11 days after the preliminary). I could see $10-$12/share. I've seen 300-350% premiums in microcap biotech before but have hard time imagining a bigger premium than that. The math should be pretty easy, avoid 325 million milestones and maybe 175 million/ + royalties on peak annual tebi sales to 2041. (estimated by $GSK ) So pay 800 million to avoid 2.5 billion + future royalties/milestones? Let's go.
0 · Reply
Buy_SoFi
Buy_SoFi Apr. 24 at 7:52 PM
$1.00+ by EoY Ferring already partnered with $TLTFF and I can only assume the new cohort of test patients are in the process of being treated for NMIBC. More partners will probably knock on the door; MIBC, GBM/Brain, Lung, pancreatic and HSV topical treatment. This has a multi-dollar buyout written all over... $IBRX $GSK $CGON $JNJ
0 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 5:42 PM
$SPRO totally anecdotal and likely confirmation bias -- but did quick search on LinkedIn "reactions" on Spero posts. Historically 3-5 Board members react, and Esther. For the March post, only the COB reacted. Looked at various board member profiles and it is not like they aren't active on LinkedIn -- they've all been reacting to stuff as recently as this week including Esther. Wonder if they are purposefully avoiding SPRO social media posts. Just a random observation. cc $GSK
0 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 3:59 PM
Crazy how correlated / linked $GSK $SPRO are but it does makes sense. GSK might have started its reversal into its earnings report next week. SPRO saw little buying pressure at same time
1 · Reply
zerodayrounder
zerodayrounder Apr. 24 at 1:51 PM
$CGEN wins the first lap to 3 $SPRO weak along with $GSK
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 23 at 11:26 PM
REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge $REGN $LLY $GSK $ABBV $AMGN https://stocktwits.com/news/equity/markets/regn-becomes-final-major-drugmaker-to-sign-trump-s-drug-pricing-pledge/cZBQQQSReT5
0 · Reply
zerodayrounder
zerodayrounder Apr. 23 at 10:42 PM
$SPRO still riding the moving averages higher (9ema, 20/50/200sma), 4 green weekly bars. Pullbacks on light volume vs hard rejection. These guys really should sell ahead of PDUFA -- I'm sure they are good this time with $GSK leading the process -- but don't need another SPRO 2022 or GRCE from today. Makes no sense to give a caretaker CEO the keys to huge amount of capital to fund risky new ventures when all the scientists were let go. Could she really articulate on Q1 earnings call the strategy moving forward and why investors should vote yes on Proposal 4? She's got huge options/RSUs to go riding off to Cape Cod or the Hamptons this summer. and the CEO/corporate counsel apparently weren't participating in woke corporate social responsibility on the Charles River Esplanade yesterday.
0 · Reply
SnapCrackleStop
SnapCrackleStop Apr. 23 at 10:25 PM
$SCYX I am cautiously optimistic. The attack was feeble and we rose in the worst of market days. Some encouraging signs. We will see revenue from $GSK this year. I don’t see the stock declining below $1 significantly if at all. The shares are up from .69 and chart is telling us that more gains lie ahead. I think the reverse split will not be imposed or needed. The share count has no real affect on business performance. Trials continue pre funded through 2027 or longer. I think the stock is under accumulation by some big boys. The private placement/ warrant deal is going to benefit longstanding holders not shorts as warrant deals sometimes do. These institutional players are in for a multi bagger. Not just a double your money. No, this is something much greater. As mentioned….I am optimistic to say the least. $$$
1 · Reply
Buy_SoFi
Buy_SoFi Apr. 23 at 6:01 PM
$TLTFF <---- Multi-multi bagger in the making. Mark this post. $CGON $MRK $IBRX $GSK
0 · Reply
Buy_SoFi
Buy_SoFi Apr. 23 at 4:14 PM
$TLTFF Keeps moving up... Still cheap! Don't miss out... - HSV Topical (better than anything on market) - NMIBC - MIBC - Brain/GBM - Lung - Ruvidar + Rutherin - Ferring Partnership $MRK $CGON $IBRX $GSK
0 · Reply
zerodayrounder
zerodayrounder Apr. 23 at 2:47 PM
You couldn't tell by the volume in $SPRO today, kind of unusual Form 14D-9 or DEF 14A incoming? $GSK appears like they unloaded final buying power in share buyback plan yesterday.
1 · Reply
zerodayrounder
zerodayrounder Apr. 22 at 11:32 PM
$SPRO also not pictured for Earth Day clean up on the Esplanade: Will Cushing, General Counsel, and another person who is VP of Legal with M&A experience according to her LinkedIn. Perhaps Esther (CEO/CFO), the legal team and Board the only people working this week. LFG $GSK
0 · Reply
zerodayrounder
zerodayrounder Apr. 22 at 6:23 PM
Hey at least $SPRO 11 employees are doing their part for Earth Day! Is Esther taking the photo or posted up in NYC? cc $GSK
0 · Reply
SlowMo71
SlowMo71 Apr. 22 at 3:31 PM
$GSK why are shorts working so hard in this? Shorts are sweaty and there are so many easier targets.
0 · Reply
zerodayrounder
zerodayrounder Apr. 22 at 2:39 PM
$SPRO needs an explosion in volume to make it obviously obvious. I'm not sure PDUFA is a massive catalyst for SPRO given GSK owns 90% of the upside & there is risk SPRO Board and c-suite does something dumb. The catalyst is being cleaned up by $GSK and for them to avoid ~$2.5 billion in milestones/royalties owed to Spero for tebipenem.
1 · Reply
zerodayrounder
zerodayrounder Apr. 21 at 8:40 PM
$SPRO clicking a little volume over 2.80 close on low volume day. ESCMID wrapped today. $GSK smoked with other Big Pharma names. M&A ramping in biotech -- GSK focused on smaller bolt-on deals with established science, and undervalued assets hiding in plain site. Allegedly. GSK wraps 500 million buy back tranche on April 24, earnings April 29 and they've already completed deals for RAPT ($2.2 billion) and 35Pharma ($950 million). Time for another $750-$1B deal? Put that share authorization increase nonsense to bed. No shareholders should be underwriting more risky ventures with the caretaker CEO/CFO.
0 · Reply
Buy_SoFi
Buy_SoFi Apr. 21 at 2:36 PM
$TLTFF 100% CR and survival for X-Ray activated Rutherin for MIBC. WOW! Topical Ruvidar showing better results for HSV than anything available on the market. $MRK $IBRX $CGON $GSK
0 · Reply
Quantumup
Quantumup Apr. 21 at 12:45 PM
Leerink⬆️ $TRVI's PT to $25 and reiterated at an Outperform rating. $GSK VRNA - $MRK PFE Here's what Leerink said in its note to investors: https://x.com/Quantumup1/status/2046570004691222934?s=20
0 · Reply
trenddetector
trenddetector Apr. 21 at 2:35 AM
$BMY $AZN $GSK $IBRX Gang, www.yourcancerpath.com has been updated with a plethora of useful tools for all types/subtypes of cancer. Please share it with friends and family. So much unbiased and useful info for cancer patients!
0 · Reply
zerodayrounder
zerodayrounder Apr. 20 at 5:31 PM
$SPRO there are only 2.3 million options out as of Dec 31. Those are likely mostly with Ankit and Shak who aren't involved anymore (or shouldn't be) with the last tranche granted in 2022 pre CRL blowup. The more interesting piece imo is the Board awarding 650k new options to CEO/COO at 2.23. Also, for anyone wondering if SPRO could restart 720 -- the license from Vertex was terminated in November 2025. So there really isn't anything of value at SPRO except for Tebi and there will be no restarts of 206/720. Time to sell. The british are coming, 1 if by land, 2 if by sea. 1+2 ... $12 . LFG $GSK
0 · Reply
zerodayrounder
zerodayrounder Apr. 20 at 3:48 PM
Today is Patriot's day in Boston. Hopefully the British are coming again. $SPRO $GSK
1 · Reply